Journal Logo

Simultaneous Sessions IV: Refining biomarkers for AML outcome

S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

Daver, N.1; Alfayez, M.1; Garcia-Manero, G.1; Abbas, H.1; Basu, S.2; Konopleva, M.1; Jabbour, E.1; Cortes, J. E.1; Ravandi, F.1; Kadia, T. M.1; DiNardo, C.1; Assi, R.1; Sherry, P.1; Andreeff, M.1; Estrov, Z.E.1; Pemmaraju, N.1; Takahashi, K.1; Ning, J.3; Nogueras Gonzalez, G.3; Kornblau, S.M.1; Matthews, J.1; Flores, W.R.2; Allison, J.P.2; Sharma, P.2; Kantarjian, H.1

Author Information
doi: 10.1097/01.HS9.0000564708.44567.4d
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.